This document summarizes the work of a team developing a company called CanScan to advance personalized cancer treatment. The team cultured circulating tumor cells (CTCs) from blood samples to characterize cancer cell aggressiveness and test drug responses. Key findings included that culturing CTCs could provide valuable data to guide treatment decisions. The team refined their business model to partner with diagnostic companies and provide CTC testing services to oncologists and pharmaceutical companies. Next steps involved further validating the technology and business through clinical trials and partnerships.
The document summarizes a team's final project presentation for a medical device startup called MammOptics. The team includes four members with engineering and business backgrounds working to develop a non-invasive, non-radiative breast cancer detection technology using optical spectroscopy. The presentation covers the initial technology and business model hypotheses, testing the value proposition with hospitals and doctors, and outlines the steps needed for product development, clinical trials, reimbursement, and company financing.
McKesson helps improve health care quality and patient safety while reducing health care costs.
Task Actions
Task Not Started ( 00:00:00 )
*
*
*
*
*
*
*
*
Biovays is a biomarker solutions provider that offers specialized services to support drug development from target discovery through FDA approval. Their services include biomarker selection and assay development, pharmacodynamics testing, toxicity analysis, and various in vitro and ex vivo assays. By providing biomarker analysis and expertise, Biovays aims to streamline drug development, reduce costs, and improve success rates.
The new Biograph mCT from Siemens provides intelligently reproducible quantification through three key innovations:
1. Daily quality control scans normalize system performance to ensure consistent and accurate quantitative results over time.
2. Precise co-registration of PET and CT images through innovations like SMART registration technologies provide better attenuation correction for more reliable data.
3. Intelligent software applications in syngo.via like SUVpeak, myocardial blood flow quantification, and pending tools for neurology assist in standardized, reproducible interpretation across users and time.
Maximum Speed
Engineered Clinical
Flexibility
syngo.via
Customer Care
Molecular Imaging
Biomarker Research
20
The document discusses open source drug discovery (OSDD) for neglected tropical diseases like tuberculosis. Key points:
- OSDD takes a collaborative, open innovation approach to drug discovery by involving research groups, industry, and individual participants in open data sharing.
- Their first disease target is tuberculosis, which infects over 1 million people per year and kills over 1,000 people per day.
- OSDD has built computational resources and databases with community participation to facilitate drug discovery. They have also integrated over 300 tools into their ChemBio toolkit.
- OSDD utilizes grid computing resources like the Garuda Grid in India to enable complex computational analysis for experimental biologists and chemists working on the
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Dr. Ralph Schaetzing, Manager, Strategic Standards & Regulatory Affairs, Carestream, writes about how we define “image quality” and how the definition involves numerous factors that can differ between people and technologies.
The key topics covered in the white paper that delves into the image quality debate include:
• Where image quality is affected throughout the radiographic image chain
• Understanding the three different “flavors” of image quality—objective, subjective, and performance-based
• The role medical image processing plays in determining image quality
• The three main categories of reader error in radiography—visual scanning, target recognition, and decision-making/interpretation
The document summarizes a team's final project presentation for a medical device startup called MammOptics. The team includes four members with engineering and business backgrounds working to develop a non-invasive, non-radiative breast cancer detection technology using optical spectroscopy. The presentation covers the initial technology and business model hypotheses, testing the value proposition with hospitals and doctors, and outlines the steps needed for product development, clinical trials, reimbursement, and company financing.
McKesson helps improve health care quality and patient safety while reducing health care costs.
Task Actions
Task Not Started ( 00:00:00 )
*
*
*
*
*
*
*
*
Biovays is a biomarker solutions provider that offers specialized services to support drug development from target discovery through FDA approval. Their services include biomarker selection and assay development, pharmacodynamics testing, toxicity analysis, and various in vitro and ex vivo assays. By providing biomarker analysis and expertise, Biovays aims to streamline drug development, reduce costs, and improve success rates.
The new Biograph mCT from Siemens provides intelligently reproducible quantification through three key innovations:
1. Daily quality control scans normalize system performance to ensure consistent and accurate quantitative results over time.
2. Precise co-registration of PET and CT images through innovations like SMART registration technologies provide better attenuation correction for more reliable data.
3. Intelligent software applications in syngo.via like SUVpeak, myocardial blood flow quantification, and pending tools for neurology assist in standardized, reproducible interpretation across users and time.
Maximum Speed
Engineered Clinical
Flexibility
syngo.via
Customer Care
Molecular Imaging
Biomarker Research
20
The document discusses open source drug discovery (OSDD) for neglected tropical diseases like tuberculosis. Key points:
- OSDD takes a collaborative, open innovation approach to drug discovery by involving research groups, industry, and individual participants in open data sharing.
- Their first disease target is tuberculosis, which infects over 1 million people per year and kills over 1,000 people per day.
- OSDD has built computational resources and databases with community participation to facilitate drug discovery. They have also integrated over 300 tools into their ChemBio toolkit.
- OSDD utilizes grid computing resources like the Garuda Grid in India to enable complex computational analysis for experimental biologists and chemists working on the
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Dr. Ralph Schaetzing, Manager, Strategic Standards & Regulatory Affairs, Carestream, writes about how we define “image quality” and how the definition involves numerous factors that can differ between people and technologies.
The key topics covered in the white paper that delves into the image quality debate include:
• Where image quality is affected throughout the radiographic image chain
• Understanding the three different “flavors” of image quality—objective, subjective, and performance-based
• The role medical image processing plays in determining image quality
• The three main categories of reader error in radiography—visual scanning, target recognition, and decision-making/interpretation
This document outlines key factors to consider when evaluating a potential business opportunity:
- The product idea should address a market need and take advantage of technological or market discontinuities. Execution is more important than being first.
- The market size and growth rate should be sufficiently large. Barriers to entry like intellectual property protection, network effects, and business model innovation must be considered.
- The founding team must have relevant experience and the ability to recruit talent. Sufficient capital is needed but excessive funding can be risky.
- The economic model, risks, and business plan must demonstrate a viable path to profitability and returns for investors. Bootstrapping may work if the market is small with no dominant competitors
Maintrac liquid biopsy allows quantitative detection of circulating tumor cells without fixation, isolation, or enrichment. It uses fluorochrome-labeled antibody targeting EpCAM antigen on circulating tumor cells. In contrast, Cellsearch uses fixation and enrichment procedures that lead to loss of cells and antigenicity, resulting in dead cells. Comparison of the two methods using the same blood sample from a patient showed Maintrac detected more total events and circulating tumor cells than Cellsearch. Other CTC detection technologies have limitations such as relying too heavily on EpCAM expression or assuming CTCs are larger than blood cells. Cell-free tumor DNA analysis has problems like representing destroyed cells and additional mutations from DNA degradation.
Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic ...MarketResearch.com
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Newer diagnostic tools in oncology such as liquid biopsies provide non-invasive approaches to diagnosing and monitoring cancer. Liquid biopsies analyze biomarkers found in bodily fluids and can detect circulating tumor cells, circulating tumor DNA, RNA, and exosomes shed by tumors into the bloodstream. These liquid biomarkers offer advantages over traditional tissue biopsies by being less invasive, able to capture the heterogeneity of tumors, and allow for real-time monitoring of treatment response and disease progression. Emerging technologies now allow liquid biopsies to provide genomic information that can help classify and treat cancers based on their molecular profiles rather than the organ or tissue of origin.
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...QIAGEN
A liquid biopsy is often described as a sensitive and specific blood test to detect circulating tumor cells (CTCs). CTCs, shed by both the primary and metastasized tumors, carry specific information about their origins and markers that will enable us to discover new diagnosis, prognosis and therapeutic targets. This slidedeck gives an overview of the recent progress in exploring the predictive potential of circulating biomarkers, including circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs (lncRNAs) and exosomes. Addressing both biological and technical aspects, we detail the isolation and characterization of circulating biomarkers. Challenges and solutions are also featured.
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Dr. Nick Thomas 17:00 - 17:30 Closing Remarks & Networking Drinks
Investigator, Molecular Discovery Research Principal Scientist
Glax
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Moderator: John Shah 17:00 Close
Investigator, Molecular Discovery Research Conference Producer
GlaxoSmithKline
This interactive workshop will provide a comprehensive overview of label-free cell-based
An overview of the oncology clinical trials network (CTNeT) which is being implemented throughout Texas.
The non-profit network is a first of its kind and combines the innovative science of Texas cancer centers with the expertise and resources of both academic and community oncologists throughout the state.
To learn more, visit www.ctnet.org
T1D Exchange is a not for profit organization whose mission is to accelerate therapies to the market to improve health outcomes on a path to a cure to type 1 diabetes. T1D Exchange possesses a clinic network of 69 clinics, a patient registry of 27,000 patients, a biorepository, and a patient engagement platform that builds an online community for people with type 1 diabetes.
The document discusses collaboration in biobanking to support pharmaceutical R&D activities. It notes that R&D costs are high and innovation is needed. Biobanks can help by providing samples for research into diseases. The document describes AstraZeneca's global biobank network and examples of collaborations on disease-specific biobanks for conditions like rheumatoid arthritis and COPD. It argues that more collaboration is needed through standards, infrastructure, addressing ethical issues, and meeting customer needs to sustain R&D activities.
BICR & Subjective Endpoints - Increasing Precision and Accuracy in Your Clin...JennyOShea
For many of today’s trials, the primary endpoint is a subjective assessment and depends on physician-rated or even patient-reported data, which means validation to the FDA and other regulatory agencies is automatically more difficult. For registration trials with subjective endpoints, blinded independent central review (BICR) of the trial data – including both images and other data such as laboratory and pathology data, autopsy reports, and physical descriptions – can be extremely valuable and may be executed through an endpoint assessment committee (EAC).
Applying NLP to Personalized Healthcare - 2021David Talby
Dr. David Talby discusses applying natural language processing (NLP) to personalized healthcare. He covers how state-of-the-art NLP accuracy has recently improved for tasks like clinical named entity recognition and relation extraction but that real-world solutions require specialized models optimized for domains, languages, entities, and relations. Hyper-specialized models are needed due to the complexity of clinical text.
Sage Bionetworks is launching a new platform called BRIDGE to enable open collaboration between patients, researchers, and funders. [1] BRIDGE will allow disease communities to define and contribute to research projects. [2] The goal is to involve citizen-patients more directly in research by allowing them to consent to participate, take surveys, share data, and participate in games and crowdsourcing challenges. [3] This could help shift biomedical research to be more open, collaborative, and relevant.
Event brochure for the upcoming Clinical Data Standardisation and Managment event in London, June.
The event will feature best practice case studies from CDISC
Appalla Venkataprabhakar and I presented this at the Oracle\'s Annual Clinical Development and Safety Conference 2010 at Hyderabad, India on 6th October 2010.
Stephen Friend Institute of Development, Aging and Cancer 2011-11-29Sage Base
The document proposes a new approach called Arch2POCM for drug development that moves from disease targets to clinical validation. It discusses issues with the current drug discovery process, noting $200 billion is spent annually but only a handful of new medicines are approved each year while productivity is declining. Arch2POCM would require a more data-driven and collaborative approach involving scientists, clinicians, and citizens to better link knowledge and accelerate eliminating human disease. It presents the mission of Sage Bionetworks to create a commons for evolving integrative networks to map diseases and enable discovery.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document describes a novel therapy for treating atrial fibrillation using magnetic nanoparticles directed by an electromagnetic workstation. The therapy aims to target and treat neural ganglia to cure the arrhythmia with low risk. The company aims to become the world leader in magnetic targeted nanomedicine delivery. Their team has expertise in nanomedicine, electrophysiology, and commercialization. The therapy has the potential to be safer, more economical and curative compared to current invasive and limited treatments for atrial fibrillation.
This document outlines key factors to consider when evaluating a potential business opportunity:
- The product idea should address a market need and take advantage of technological or market discontinuities. Execution is more important than being first.
- The market size and growth rate should be sufficiently large. Barriers to entry like intellectual property protection, network effects, and business model innovation must be considered.
- The founding team must have relevant experience and the ability to recruit talent. Sufficient capital is needed but excessive funding can be risky.
- The economic model, risks, and business plan must demonstrate a viable path to profitability and returns for investors. Bootstrapping may work if the market is small with no dominant competitors
Maintrac liquid biopsy allows quantitative detection of circulating tumor cells without fixation, isolation, or enrichment. It uses fluorochrome-labeled antibody targeting EpCAM antigen on circulating tumor cells. In contrast, Cellsearch uses fixation and enrichment procedures that lead to loss of cells and antigenicity, resulting in dead cells. Comparison of the two methods using the same blood sample from a patient showed Maintrac detected more total events and circulating tumor cells than Cellsearch. Other CTC detection technologies have limitations such as relying too heavily on EpCAM expression or assuming CTCs are larger than blood cells. Cell-free tumor DNA analysis has problems like representing destroyed cells and additional mutations from DNA degradation.
Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic ...MarketResearch.com
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Newer diagnostic tools in oncology such as liquid biopsies provide non-invasive approaches to diagnosing and monitoring cancer. Liquid biopsies analyze biomarkers found in bodily fluids and can detect circulating tumor cells, circulating tumor DNA, RNA, and exosomes shed by tumors into the bloodstream. These liquid biomarkers offer advantages over traditional tissue biopsies by being less invasive, able to capture the heterogeneity of tumors, and allow for real-time monitoring of treatment response and disease progression. Emerging technologies now allow liquid biopsies to provide genomic information that can help classify and treat cancers based on their molecular profiles rather than the organ or tissue of origin.
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...QIAGEN
A liquid biopsy is often described as a sensitive and specific blood test to detect circulating tumor cells (CTCs). CTCs, shed by both the primary and metastasized tumors, carry specific information about their origins and markers that will enable us to discover new diagnosis, prognosis and therapeutic targets. This slidedeck gives an overview of the recent progress in exploring the predictive potential of circulating biomarkers, including circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs (lncRNAs) and exosomes. Addressing both biological and technical aspects, we detail the isolation and characterization of circulating biomarkers. Challenges and solutions are also featured.
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Dr. Nick Thomas 17:00 - 17:30 Closing Remarks & Networking Drinks
Investigator, Molecular Discovery Research Principal Scientist
Glax
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Moderator: John Shah 17:00 Close
Investigator, Molecular Discovery Research Conference Producer
GlaxoSmithKline
This interactive workshop will provide a comprehensive overview of label-free cell-based
An overview of the oncology clinical trials network (CTNeT) which is being implemented throughout Texas.
The non-profit network is a first of its kind and combines the innovative science of Texas cancer centers with the expertise and resources of both academic and community oncologists throughout the state.
To learn more, visit www.ctnet.org
T1D Exchange is a not for profit organization whose mission is to accelerate therapies to the market to improve health outcomes on a path to a cure to type 1 diabetes. T1D Exchange possesses a clinic network of 69 clinics, a patient registry of 27,000 patients, a biorepository, and a patient engagement platform that builds an online community for people with type 1 diabetes.
The document discusses collaboration in biobanking to support pharmaceutical R&D activities. It notes that R&D costs are high and innovation is needed. Biobanks can help by providing samples for research into diseases. The document describes AstraZeneca's global biobank network and examples of collaborations on disease-specific biobanks for conditions like rheumatoid arthritis and COPD. It argues that more collaboration is needed through standards, infrastructure, addressing ethical issues, and meeting customer needs to sustain R&D activities.
BICR & Subjective Endpoints - Increasing Precision and Accuracy in Your Clin...JennyOShea
For many of today’s trials, the primary endpoint is a subjective assessment and depends on physician-rated or even patient-reported data, which means validation to the FDA and other regulatory agencies is automatically more difficult. For registration trials with subjective endpoints, blinded independent central review (BICR) of the trial data – including both images and other data such as laboratory and pathology data, autopsy reports, and physical descriptions – can be extremely valuable and may be executed through an endpoint assessment committee (EAC).
Applying NLP to Personalized Healthcare - 2021David Talby
Dr. David Talby discusses applying natural language processing (NLP) to personalized healthcare. He covers how state-of-the-art NLP accuracy has recently improved for tasks like clinical named entity recognition and relation extraction but that real-world solutions require specialized models optimized for domains, languages, entities, and relations. Hyper-specialized models are needed due to the complexity of clinical text.
Sage Bionetworks is launching a new platform called BRIDGE to enable open collaboration between patients, researchers, and funders. [1] BRIDGE will allow disease communities to define and contribute to research projects. [2] The goal is to involve citizen-patients more directly in research by allowing them to consent to participate, take surveys, share data, and participate in games and crowdsourcing challenges. [3] This could help shift biomedical research to be more open, collaborative, and relevant.
Event brochure for the upcoming Clinical Data Standardisation and Managment event in London, June.
The event will feature best practice case studies from CDISC
Appalla Venkataprabhakar and I presented this at the Oracle\'s Annual Clinical Development and Safety Conference 2010 at Hyderabad, India on 6th October 2010.
Stephen Friend Institute of Development, Aging and Cancer 2011-11-29Sage Base
The document proposes a new approach called Arch2POCM for drug development that moves from disease targets to clinical validation. It discusses issues with the current drug discovery process, noting $200 billion is spent annually but only a handful of new medicines are approved each year while productivity is declining. Arch2POCM would require a more data-driven and collaborative approach involving scientists, clinicians, and citizens to better link knowledge and accelerate eliminating human disease. It presents the mission of Sage Bionetworks to create a commons for evolving integrative networks to map diseases and enable discovery.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document describes a novel therapy for treating atrial fibrillation using magnetic nanoparticles directed by an electromagnetic workstation. The therapy aims to target and treat neural ganglia to cure the arrhythmia with low risk. The company aims to become the world leader in magnetic targeted nanomedicine delivery. Their team has expertise in nanomedicine, electrophysiology, and commercialization. The therapy has the potential to be safer, more economical and curative compared to current invasive and limited treatments for atrial fibrillation.
The document discusses the growth of genomic sequence data due to falling costs of DNA sequencing. This creates both a "big data" problem of how to store and analyze large amounts of data, as well as a "diminishing discovery" problem as it becomes harder to find new discoveries within the data. The document proposes several solutions to these problems including pre-competitive collaboration between organizations to share data and analytics platforms. It provides examples of existing data sharing platforms like tranSMART and describes how next generation sequencing is revealing different types of human genetic variation including single nucleotide polymorphisms and their role in pharmacogenomics.
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
Team Networks - 2022 Technology, Innovation & Great Power CompetitionStanford University
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, networks
Team LiOn Batteries - 2022 Technology, Innovation & Great Power CompetitionStanford University
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, LiOn Batteries
Team Quantum - 2022 Technology, Innovation & Great Power CompetitionStanford University
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Quantum
Team Disinformation - 2022 Technology, Innovation & Great Power CompetitionStanford University
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Disinformation
Team Wargames - 2022 Technology, Innovation & Great Power CompetitionStanford University
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Wargames
Team Acquistion - 2022 Technology, Innovation & Great Power Competition Stanford University
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Acquistion
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Stanford University
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, climate
The document describes a team's efforts to commercialize a new protein quantification technology called PLA-Seq. After initially thinking the technology's value propositions of lower cost, faster throughput, and lower sample volume would appeal to pharmaceutical and personalized health companies, the team conducted customer interviews and learned accuracy was more important than cost to most customers. They also found their target markets should be preclinical biotech and academia rather than personalized health or CROs. The team incorporated their business and pivoted their marketing strategy and funding plans accordingly based on learnings outside of the building.
The document summarizes the development of Invisa Bio over 10 weeks as they pivoted between different medical applications and solutions for their self-assembling medical device technology. They initially focused on manufacturing and delivery but shifted to leveraging drug delivery mechanisms. They considered applications in cardiology, neurology, and orthopedics before focusing on brain aneurysms based on feedback from physicians. The company incorporated, raised funding, and began shadowing doctors to further develop their technology to address unmet needs in difficult to reach areas.
(1) The document describes the journey of a team developing a saffron supplement product to address mental health issues like anxiety and depression.
(2) It started with the goal of targeting adults aged 18-40, but through customer interviews and testing, they learned that teenagers were more interested in an anti-anxiety gummy product.
(3) Key lessons included the challenges of building the right team, navigating advice, knowing when enough customer feedback has been received, and setting individual and project milestones. The team is now continuing work over the summer to further develop the product.
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Stanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, Army venture capital
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Stanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve Blank, Army Venture capital
Team Catena - 2021 Technology, Innovation & Great Power CompetitionStanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, economic coercion,
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionStanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, space force
Team Drone - 2021 Technology, Innovation & Great Power CompetitionStanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, c3i, command and control
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionStanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, semiconductors
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionStanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, Army venture capital
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Stanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, venture capital
Lecture 8 - Technology, Innovation and Great Power Competition - CyberStanford University
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, hacking for defense, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, Michael Sulmeyer, cybercom,USCYBERCOM
The simplified electron and muon model, Oscillating Spacetime: The Foundation...RitikBhardwaj56
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
How to Build a Module in Odoo 17 Using the Scaffold MethodCeline George
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
Main Java[All of the Base Concepts}.docxadhitya5119
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
Assessment and Planning in Educational technology.pptxKavitha Krishnan
In an education system, it is understood that assessment is only for the students, but on the other hand, the Assessment of teachers is also an important aspect of the education system that ensures teachers are providing high-quality instruction to students. The assessment process can be used to provide feedback and support for professional development, to inform decisions about teacher retention or promotion, or to evaluate teacher effectiveness for accountability purposes.
Assessment and Planning in Educational technology.pptx
Can scan final 2012 berkeley
1. Advancing
Personalized Medicine
one cancer patient at
a time.
James Lim, Ph.D., Nelson Chan, Ph.D., Dale Fedun, Brian Feth
Mentor: John Feilders (CMEA Capital)
Lawrence Berkeley National Laboratory
University of California, Berkeley – Haas School of Business
*73 interviews
1
2. Team of scientists and MBA students
James Lim, PhD
Scientist
Experience: Seven years of cancer cell microscopy
Expertise: Live-cell microscopy and cancer cell biology
Dale Nelson James Brian
Nelson Chan, PhD
Scientist
Experience: Seven years of cancer research
Expertise: Biochemical and toxicological analysis mediating cancer cell death
Brian Feth
MBA
Experience: Five years in life sciences business strategy consulting and private equity
Expertise: Business model development and project management
Dale Fedun
MBA
Experience: Twelve years in creating and managing business IT programs
Expertise: Business model and IT system development
2
2
3. Circulating Tumor Cells (CTCs): Initial Idea
Circulating tumor cells Oncologists & Pathologists
Cancer cells that have Does my patient have any
detached from the CTCs?
tumor and are How aggressive are they?
circulating in the blood
stream
Capture and grow CTCs
Video technology to characterize aggressiveness
3
3
4. Testing our initial hypotheses: Focus on
customer segments and value propositions
Diagnosis/ Direct sales
Advocacy Groups Consultation
Prognosis: Conferences Clinicians
Regulatory Cell-
Cell validation MD office Adverts Oncologists
Agency Characterization
Patient mgmt Publications Pathologists
Oncologists Database building
Drug selection Patient Patients
Physicians Assoc Disposal
advertisements
R&D
Minimally invasive
Low cost
Specific
IP Fast
Patient Database Hospital MD
office, HMO
Advocacy Groups
Pharma
Variable: Media, plastic ware, personnel, computing
Service per time point (service/use)
storage, building space
Kits / Reagents (patients only)
Fixed: Centrifuge, microscopes, freezers, incubators,
and hoods
4
4
5. Get out of the Building! Talked to customers and
partners to test our hypotheses
• Visited local hospitals and
clinics
• Called nurses and patients to
get perspectives
• Spoke with physician and
patient advocacy groups
• Hit the rolodex, plan interviews
far in advance, daisy-chain to
new contacts
5
5
6. Key people we spoke to:
Dr. Leisha Emens
Dr. John Siebel
Dr. Ana Aguilar
Dr. Scott North
Dr. George Sledge
Dr. Alan Venook
Dr. Peter Eisenberg
Dr. Cassandra Lee
Dr. Balaram Puligandla
Dr. Ken Pritzker (CEO)
Dr. Doug Tkachuk (CMO)
Dr. Scott Minick (CEO)
6
6
7. Determining our customers
Oncologist Pathologist
Patient management Sample management
• Oncologists decide • Pathologists perform in-
what tests to order, house tests and
when, and how often facilitate contracts with
service providers
• Primary customer • Less important
7
7
8. Key messages from Oncologists:
Dr. Siebel
“Culturing a patient’s CTCs to test efficacy of therapies would be
valuable, if you could prove in vitro results are replicated in vivo.”
Dr. Sledge
“Don’t give us more data. Tell us which drug to use for
each patient.”
Dr. North
“Definitively knowing if a patient should get chemo
would be a major breakthrough in oncology.”
8
8
9. What we learned from similar companies:
RNA Diagnostics
“The space is crowded; there are
many start-ups enumerating CTCs”
LifeLabs
“The clinical setting is difficult and
can take years to get to market”
Bind Biosciences
“CTC enumeration is not as useful and provides a limited
sample. Your approach is unique and overcomes key
limitations.”
9
9
11. We are unique in our ability to culture CTCs
Technology Capability
Company Product Technology Channel
Isolate Count Analyze Culture
Parsortix Filter Kits
CellSearch Antibody Kits
Vita-Assays Substrate Kits
Mvs360 Antibody Device
OncoCEE Microfluidics CLIA labs
LiquidBiopsy Antibody CLIA labs
ISET device Filter Device
On-Q-ITY
chip
Microfluidics Device
ApoStreamTM
Technology
Microfluidics Device
- Substrate CLIA?
*This is an abbreviated list
11
11 Class 8 - Update 3.19.2012
12. Cell culture value proposition
Identify and
enumerate CTCs
Characterize
growth potential
Culture Test
Chemotherapies
CTCs
Test CTCs for
biomarkers
12
12
13. Updated business canvas
Consultation
Characterization Provide new data Direct sales
Advocacy Groups
Database building to improve Conferences
Regulatory
R&D treatment MD office Adverts
Agency Oncologists
decisions Publications
Oncologists Treatment
Patient
Physicians Assoc determination in
advertisements
vitro
Pharmaceutical
Researchers
IP
Patient Database Hospital MD
CLIA certification office, HMO
Advocacy Groups
Pharma
Variable: Media, plastic ware, personnel, computing
Service per time point (service/use)
storage, building space
Kits / Reagents (patients only)
Fixed: Centrifuge, microscopes, freezers, incubators,
and hoods
13
13
14. Alternative market model
• Urged by the teaching team to
Private
CMS
payer/MAC explore alternative markets
Hospital / Clinic • Interviewed clinical research
Lab Advisory
Commi ee
Oncologists ASCO / organizations, pharma/biotech,
NCCN
and academics
CanScan
Influence
Payment
Sets rate
14
14
15. Alternative market model
• Urged by the teaching team to
explore alternative markets
• Interviewed clinical research
organization, pharma/biotech,
and academics
15
15
16. Partnering with Quest Diagnostics
• Covers 130 countries
• 2000 sites in the US
16
16
19. Key people we spoke to:
Dr. Ming Tong
Dr. Brian Edmunds
Dr. Philip Tagari
Dr. Thomas Fare
Dr. Sal Russelo
Dr. Steve Labkoff
Dr. Lisa Hewitt
Dr. Zemin Zhang
Dr. John Sninsky
Dr. Scott Patterson
Dr. Lawrence LaPointe
Dr. Slyvie Sakata
19
20. New opportunity: Pharmaceutical drug testing
“A better human-like in vitro models
for high throughput screening”
Head Research Development
Amgen “This would be a powerful platform to
test personalized drugs”
VP Business Development
“Testing drug on circulating cancer cells Merck
could offer us better end-points to
evaluate drug candidate effectiveness”
Head Research Development “Come work with us, we will be
Abbott Laboratories your first customer!”
CEO
Clinical Genomics
20
20
22. Current business canvas
Cell charact.
Database dev. Provide new data Personal
Str. Alliances:
Product/IP Dev to improve assistance,
local hospitals -
Treatment sel. treatment Automated
Marin Gen Oncologists
In vitro screening decisions. services
Hospital, CHRC
Oakland. Consultation
Cell Line bank. Pharmaceutical
Cancer drug
Med Device – Researchers
efficacy screening.
Medtronic, Baxter
IP CTC biomarker
Tech Validation- discovery
Patient Database Sales force
Clinical Genomics
CLIA certification
CPT Code
Joint Venture:
Quest Diagnostics
Variable: IP Licensing, lab supplies, personnel, IT,
Usage fee per CTC scan, data/consulting
specimen transportation
sales, cell line sales, instrument/kits product
Fixed: Lab equipment, lab space, SG&A, R&D
model
22
22
23. Intellectual property progress
Who owns What is Patent New IP
the IP? patentable ? process generation
Progress
Spoke to Berkeley Initial meeting with Provisional and New IP for keeping
Tech Transfer IP lawyer Utility application competitors away
Provisional Utility Application International
Patent (US) Patents
12 months
Up to 30 months
23
23
24. Path to Revenues
Mechanistic
PoC
Concept • Cell culture
feasibility
Validation
• Mouse models ✓
Requirements • 20-30 human
blood samples
• $10-15K
Cost ($100K+ equip)
• Access to lab
Time 2-3 Months
24
24
25. Path to Revenues
Mechanistic Technology
PoC Scope
Concept • Cell culture • Proof of
feasibility Concept in
Validation
multiple cancer
types
• Reproducibility
• Mouse models • 100+ human
Requirements • 20-30 human blood samples
blood samples
• $10-15K • $50K+
Cost ($100K+ equip) • Incubator space
• Access to lab
Time 2-3 Months 3-6 Months
25
25
26. Path to Revenues
Mechanistic Technology Biomarker
PoC Scope Validation
Concept • Cell culture • PoC in multiple • CTC / tumor
feasibility cancer types characterization
Validation
• Reproducibility
• Mouse models • 100+ human • Genomic / Pharma
Requirements • 20-30 human blood samples Proteomic
blood samples • Morphology Sales
• $10-15K • $50K+ • Outsource
Cost ($100K+ equip) • Incubator space (~$20K)
• Access to lab • Service/kit dev.
Time 2-3 Months 3-6 Months 1-2 Months
26
26
27. Path to Revenues
Mechanistic Technology Biomarker Clinical
PoC Scope Validation Validation
Concept • Cell culture • PoC in multiple • CTC / tumor • Patient
feasibility cancer types characterization stratification
Validation
• Reproducibility
• Mouse models • 100+ human • Genomic / • Phase II trial Clinical
Requirements • 20-30 human blood samples Proteomic (~200 patients)
blood samples • Morphology • Treatment use
Sales
• $10-15K • $50K+ • Outsource • Outsource
Cost ($100K+ equip) • Incubator space (~$20K) ($500K-$1M)
• Access to lab • Service/kit dev. • CPT Code/CLIA
Time 2-3 Months 3-6 Months 1-2 Months 1-2 Years
27
27
32. Choosing Partners: Decision Matrix
LAB / Incubator Proof of Concept COST TIME IP issues ?
0
$
$
$$
$
Hospital Trial
$$
$$$
32
32
33. Next Steps
FDA Clinical
Trials
**Grants and
Investments
IP and
Patents
New IP
Hospital trial generation
Clinical **Grants and
Validation Investments Personalized
treatment of
LAB patients
Complete IP
Publications protection
Incorporating
CanScan
Proof of
Concept New IP Revenue from
**Grants and generation Pharma
Investments
Record of
Invention
Lab Certification Licensing
New IP
Patent filing (CLIA) royalties
generation
Grow cancer cells
April 2012 May 2012 July 2012 Dec. 2012 Spring 2013
33
33
36. The CanScan Vision: Personalized Diagnostics
Platform for:
New drug testing
Personalized
Chemosensitivity
testing
Biomarker
Discovery
36
36
37. Thank you!
James Lim, Ph.D., Nelson Chan, Ph.D., Dale Fedun, Brian Feth
Mentor: John Feilders (CMEA Capital)
Lawrence Berkeley National Laboratory
University of California, Berkeley – Haas School of Business
37
37
38. Appendix
James Lim, Ph.D., Nelson Chan, Ph.D., Dale Fedun, Brian Feth
Mentor: John Feilders (CMEA Capital)
Lawrence Berkeley National Laboratory
University of California, Berkeley – Haas School of Business
38
38
39. CanScan Technology: Background on CTCs
Collection of cells that have the
ability to ‘metastasize’ away from
the primary tumor
Enumeration of CTCs was a better
indicator of disease progression
than traditional imaging
techniques
CTCs are potentially a valuable
diagnostic and prognostic tool
39
39
40. Current CTC technologies: Limitations
Competitors
Marker-Dependent Marker-
INDEPENDENT
Method leads to Method allows for
cell death LIVE cells to move
and grow
Genomic and Easy to enrich cells
Proteomic analysis for genomic and
is difficult proteomic analysis
Technological Technological
DEAD-END HIGHWAY
40
40
41. Improving CTC detection and characterization
Invade
Current detection and
characterization methods for CTCs
fail to address the most intriguing
aspect of their biology:
Adhere
CTCs are programmed to
invade, adhere and
Proliferate proliferate.
41
41
44. Health insurance reimbursement is necessary
precondition for hospitals to use our service
Private insurance or Medicare reimbursement requires:
Evidence of
• Double-blinded, placebo controlled clinical trial with several
hundred participants will be needed
Clinical Utility
− Must demonstrate the detection is accurate and repeatable
− Must demonstrate improved decision-making ability for physician
linked to better patient outcomes
Assignment of
• Codes are assigned by the AMA (CPT code) and CMS (HCPCS
code) semi-annually with editorial panel approval (12-18 mo)
a Billing Code
− CanScan’s likely coding: HCPCS Level II or CPT category III*
− Veridex CellSearch received code in Nov. 2011 for CTCs
− CanScan will likley need new code (non-immunologic)
* Coding used for non-FDA approved service billed by suppliers other than physicians
44
44
45. CMS requires that all laboratory testing on human
specimens be CLIA certified
• CMS regulates all laboratory testing (except research) performed on humans in the
U.S. through the Clinical Laboratory Improvement Amendments (CLIA)
− CLIA certification requires accreditation from a CLIA-certified provider (e.g., CAP)
− CLIA covers approximately 5,500 independent labs (225,000 total labs)
− We will likely need to apply for CLIA certification for High Complexity tests *
• FDA regulates commercially marketed in vitro diagnostic tests under the Clinical
Laboratory Improvement Amendments (CLIA), not a requirement for CanScan
* Immunicon received approval as a High Complexity lab in 11/2006
45
45
46. The market size for metastatic cancer diagnostics in
the US is estimated to be $805 Million / year
Methodology: Value: Explanation: Source:
U.S. population size 313M Total U.S. population in 2012 U.S. Census
x Bureau estimate
U.S. incidence of all cancers 0.512% Treatment is typically given in ACS Cancer Facts
the first year following diagnosis & Figures 2011
=
Total U.S. cancer incidence 1.6 M
x
% diagnosed with regional Cancers that spread to local or NCI SEER 2011
39.4%
or distant cancers distant lymph nodes or organs data
=
Patients w/ regional or
628,420
distant cancers
x
Cost of diagnosis and Weighted avg. patient cost p.a. JAMA. 2010;
$1,285
monitoring (annually) for imaging procedures (2008) 303(16):1625-1631
=
Market size for metastatic
$805M
cancer Dx / monitoring
46
46
47. Technology: Capture and Culture CTCs
1. Draw blood 2. Separate blood through centrifugation
3. Plate cancer cells on S-SUBSTRATES, let them grow 4. Image cancer cells
47
47
48. Technology: Enrichment and Selection
Detailed comparison of
CTCs from a single patient
Determining the genetic and proteomic
makeup of CTC subgroups
48
48
Editor's Notes
Our team has a depth of scientific and business experience in our core markets
We initially believed we were a visualization company with a novel approach to characterizing cancer Create value by enumerating and characterizing the aggressiveness of CTCsTarget customers in hospital (i.e., pathologist, oncologist, patients) Use a CLIA-based service model to deliver value to customersUse direct sales channels to reach customers in the hospital
When we entered the class, we thought our target markets were physicians managing clinical trials, pathologists (traditionally the main cancer diagnostician at a hospital), oncologists, and patients. And we were fairly certain the patients might be interested in purchasing kits to look for cancer recurrence.
Interview summary slideShowwe had discussions with oncologists and competitors from these institutions(see mammoptics slide 10)
What oncologists do, what pathologists do. Focus on oncologists.Need a new approach to get interviews with oncologists. Hit the rolodex, plan interviews far in advance, daisy-chain to new contactsPathologists do not order tests, and usually don’t decide where to source a test from, so are less important to our business
key learnings from oncologists (value proposition)
Title and company for “quotes”
Leading up to this slide, we need to be developing the case for a pivot into a cell culture company. John didn’t seem clear on how/why we decided this.
Change technology column to: Dead vs live cellsThe point of this slide is simply that right now culturing is a unique proposition. Do not focus on all competitors or what they do or how we will compete. Make the simple point of for now we have a unique proposition.
Value Proposition of Cell CulturingCell culture node in the middleBubbles appearing around showing value prop of cell culturingSimilar to mammoptics slide 19
This is about "reimbursement“. Use our original slide, then on the next slide overlay “start-ups can die while waiting for a CPT code"(mammoptics slides 11&12)The point here is CPT Code
This is about "reimbursement“. Use our original slide, then on the next slide overlay “start-ups can die while waiting for a CPT code"(mammoptics slides 11&12)The point here is CPT Code
To Do:Quest logo, map to show they are national-what Quest does-they would build it for us-10% of revenues
To Do:Quest logo, map to show they are national-what Quest does-they would build it for us-10% of revenues
To Do:Quest logo, map to show they are national-what Quest does-they would build it for us-10% of revenues
Interview summary slideShowwe had discussions with oncologists and competitors from these institutions(see mammoptics slide 10)
They are willing to purchase the CTCS. Also they are willing to outsource the service to us. _____________AnimationThis is the far better than our cancer cell modelsThis would be a powerful companion diagnostic tool to support personalized medicinesThis can improve personalized medicineCulture CTC is good, this can change how we developWe need it, this is whyNo regulation to serve usWe’ll pay for it when you can prove itSame format as previous bubble slides: pharma has a large unmet need for better human-like in vitro HTS models (quotes).
We need it, this is whyNo regulation to serve usWe’ll pay for it when you can prove itSame format as previous bubble slides: pharma has a large unmet need for better human-like in vitro HTS models (quotes).
Development timeline (milestones)graph of costs over time Similar to mammoptics slides 57 – 63 (but less busy)
Development timeline (milestones)graph of costs over time Similar to mammoptics slides 57 – 63 (but less busy)
Development timeline (milestones)graph of costs over time Similar to mammoptics slides 57 – 63 (but less busy)
Average clinical trial cost per patient is $6,000, which would imply $1.2M for a 200 patient trial. However, the cost of trials is a range that we think we’re on the low end of since it would be existing drugs used
Average clinical trial cost per patient is $6,000, which would imply $1.2M for a 200 patient trial. However, the cost of trials is a range that we think we’re on the low end of since it would be existing drugs used
Average clinical trial cost per patient is $6,000, which would imply $1.2M for a 200 patient trial. However, the cost of trials is a range that we think we’re on the low end of since it would be existing drugs used
Average clinical trial cost per patient is $6,000, which would imply $1.2M for a 200 patient trial. However, the cost of trials is a range that we think we’re on the low end of since it would be existing drugs used
Average clinical trial cost per patient is $6,000, which would imply $1.2M for a 200 patient trial. However, the cost of trials is a range that we think we’re on the low end of since it would be existing drugs used
Overview of failed trials – most recent, one FDA approved device / comprehensive overview of CTCs in the clinical setting. TRY TO FIND TRIALS FOR PEDIATRICS – this might be the first of its kind… / emphasize that.
Overview of failed trials – most recent, one FDA approved device / comprehensive overview of CTCs in the clinical setting. TRY TO FIND TRIALS FOR PEDIATRICS – this might be the first of its kind… / emphasize that.
Overview of failed trials – most recent, one FDA approved device / comprehensive overview of CTCs in the clinical setting. TRY TO FIND TRIALS FOR PEDIATRICS – this might be the first of its kind… / emphasize that.
Historical significance, what are they, what are some of the unique attributes of these cells / cite tons of references
Marker/antibody based approaches have inherent limitationsLowsensitivity, specificity, and reproducibility.
Marker/antibody based approaches have inherent limitationsLowsensitivity, specificity, and reproducibility.
Overview of failed trials – most recent, one FDA approved device / comprehensive overview of CTCs in the clinical setting. TRY TO FIND TRIALS FOR PEDIATRICS – this might be the first of its kind… / emphasize that.
Average clinical trial cost per patient is $6,000, which would imply $1.2M for a 200 patient trial. However, the cost of trials is a range that we think we’re on the low end of since it would be existing drugs used
Overview of failed trials – most recent, one FDA approved device / comprehensive overview of CTCs in the clinical setting. TRY TO FIND TRIALS FOR PEDIATRICS – this might be the first of its kind… / emphasize that.
Overview of failed trials – most recent, one FDA approved device / comprehensive overview of CTCs in the clinical setting. TRY TO FIND TRIALS FOR PEDIATRICS – this might be the first of its kind… / emphasize that.